# The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

> **NCT04949191** · PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 10 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** Pemigatinib
- **DRUG:** Retifanlimab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04949191
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-08
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** A business decision due to availability of commercial drug and other options for accessing study drug treatment.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04949191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04949191, "The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04949191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*